Clinical Trial

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Protocol Amendment History 5 changes
notable Trial sites expanded: 312 -> 325 locations 2026-08-14
notable Enrollment increased: 880 -> 1160 participants 2026-07-15
notable Trial sites expanded: 303 -> 312 locations 2026-07-15
notable Primary completion pushed: 2029-02-05 -> 2030-07-01 2026-07-15
minor Completion pushed: 2029-10-08 -> 2030-07-01 2026-07-15
Trial Details
NCT Number NCT06692738
Lead Sponsor AstraZeneca
Conditions Non-small Cell Lung Cancer
Enrollment 1,160 participants
Start Date 2024-11-18
Primary Completion 2030-07-01 (estimated)
Study Completion 2030-07-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-13